JACKEDFORUMS

Fat Loss & Metabolic

Incretin mimetics and lipolytic peptides — the GLP-1 class and its relatives.

9 compounds

Fat Loss

Animal only

5-Amino-1MQ

5-amino-1-methylquinolinium iodide · 5A1MQ

Oral NNMT inhibitor aimed at fat-cell metabolism and NAD+ salvage. Mouse data only.

Dose
50–150 mg
Frequency
once daily
Half-life

Fat Loss

Human trials

AOD-9604

AOD9604 · Tyr-hGH(177-191)

Modified hGH tail fragment sold for lipolysis without the IGF-1 rise of growth hormone.

Dose
250–500 mcg
Frequency
once daily
Half-life
3 min

Fat Loss

Human trials

Cagrilintide

AM833 · Cagri

Long-acting amylin analogue run weekly for satiety, usually alongside a GLP-1.

Dose
0.3–4.5 mg
Frequency
once weekly
Half-life
6.6 days

Fat Loss

Animal only

HGH Fragment 176-191

HGH Frag · Frag 176-191

The C-terminal tail of growth hormone, sold for fat loss on almost entirely rodent evidence.

Dose
125–500 mcg
Frequency
Once daily, fasted (many split it into two 250 mcg doses)
Half-life

Fat Loss

Human trials

Liraglutide

Lira · Victoza

Daily first-generation GLP-1 agonist; weaker and more injection-heavy than the weekly analogues.

Dose
0.6–3 mg
Frequency
Once daily
Half-life
13 h

Fat Loss

Human trials

Retatrutide

Reta · LY3437943

Investigational weekly triple GIP/GLP-1/glucagon agonist with the largest weight loss seen yet.

Dose
1–12 mg
Frequency
Once weekly
Half-life
6 days

Fat Loss

Human trials

Semaglutide

Sema · Ozempic

Long-acting GLP-1 agonist dosed weekly; the reference compound for appetite-driven fat loss.

Dose
0.25–2.4 mg
Frequency
Once weekly
Half-life
7 days

Fat Loss

Human trials

Survodutide

BI 456906 · BI-456906

Weekly glucagon/GLP-1 dual agonist that raises energy expenditure as well as cutting appetite.

Dose
0.3–6 mg
Frequency
once weekly
Half-life
6 days

Fat Loss

Human trials

Tirzepatide

Tirz · Mounjaro

Weekly dual GIP/GLP-1 agonist; beats semaglutide on total weight loss in head-to-head data.

Dose
2.5–15 mg
Frequency
Once weekly
Half-life
4.9 days

Other classes